ACRV

Acrivon Therapeutics, Inc. Common Stock (ACRV) Economic Moat Analysis (2026)

Invetso Score: 1.8/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.0 (Weak)

ACRV’s negative TTM ROIC and ROCE indicate it is not yet monetizing any proprietary asset base at a level that supports durable pricing power versus peers.

The absence of disclosed 5-year margin or return history in the provided metrics limits evidence of persistent brand, IP, or regulatory advantages relative to competitors.

With no visible profitability premium, any intangible assets appear insufficient today to translate into superior retention or margin durability versus peers.

Switching Costs

Score:

A TTM cash conversion cycle of 595.2 days suggests working-capital intensity rather than customer lock-in, which is inconsistent with meaningful switching costs versus peers.

Negative ROIC and ROCE imply customers are not currently paying for a differentiated embedded solution that would make replacement costly or operationally disruptive.

The provided metrics do not show recurring revenue, contract stickiness, or integration depth, so switching costs appear weak relative to stronger peer models.

Network Effects

Score:

The available metrics do not evidence user-to-user, data, or ecosystem feedback loops that would compound value over time versus peers.

Negative returns on capital suggest the business is not yet capturing scale benefits that typically accompany strong network effects.

Without signs of accelerating retention, monetization, or platform dependency, network effects appear absent or immaterial today.

Cost Advantage

Score:

A zero asset turnover reading and deeply negative ROIC indicate the company is not demonstrating operating efficiency that would support a structural cost advantage versus peers.

The very long cash conversion cycle points to capital drag rather than procurement, manufacturing, or distribution advantages.

No provided metric shows lower unit economics or superior margin conversion, so cost advantage appears weak and not durable.

Efficient Scale

Score:

The provided data do not indicate a profitable niche with constrained capacity where scale would deter entry or preserve margins versus peers.

Negative capital returns suggest the business has not yet reached an efficient scale position that would make additional competition uneconomic.

Absent evidence of stable excess returns or industry concentration, efficient scale appears limited and not a source of durable moat today.

Overall Score

Score:

ACRV currently shows no clear durable moat versus peers because the supplied metrics point to negative capital returns, weak efficiency, and no evidence of switching costs, network effects, or efficient scale.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Acrivon Therapeutics, Inc. Common Stock. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →